Doctronic, a pioneering company offering a personal AI doctor platform, has successfully closed a $40 million Series B funding round. The investment was co-led by Abstract and Lightspeed Venture Partners, with continued support from existing investors. This new capital injection elevates the company's total funding to $65 million, signaling strong investor confidence in its innovative approach to healthcare.
Strategic Capital for AI Healthcare Expansion
This latest funding round marks a significant milestone for Doctronic, building upon a $20 million Series A and a $5 million investment secured last year. The participation of notable firms such as Seven Stars, Union Square Ventures, Tusk Ventures, and Mantis underscores the growing momentum behind AI-driven medical solutions. The substantial capital will fuel the company's next phase of strategic growth and market penetration.
With the new funds, Doctronic plans to expand its services into pediatrics and deepen its integration within the healthcare ecosystem. The company aims to forge new partnerships with academic medical centers, payers, digital health platforms, and hospital systems. Co-CEO Matt Pavelle highlighted the vision for Doctronic to serve as a digital front door, efficiently routing patients and providing unlimited primary care at a predictable cost.
Innovating Patient Care with Autonomous Technology
At its core, the New York-based company provides a HIPAA-compliant, AI-powered platform available 24/7 to autonomously make clinical decisions. The system engages users by providing detailed medical explanations for their health questions and asking relevant clinical questions in return. This creates an interactive and informative initial point of contact for patients seeking medical guidance.
Beyond its AI chatbot, the platform offers a seamless transition to human care by providing access to licensed physicians through video visits. This service is available for a standard insurance copay or a flat fee of $39 for those without insurance. This hybrid model ensures that patients receive comprehensive care, blending advanced technology with traditional medical expertise.
Pioneering AI in Prescription Services
Doctronic has already achieved a landmark milestone in the application of its technology through a partnership with the state of Utah. Announced in January, this collaboration enables the company's autonomous AI system to legally renew prescriptions for patients with chronic conditions. This initiative established Doctronic as the first entity to use an AI platform for legally prescribing routine medication refills.
Building on this success, the company is actively pursuing opportunities to replicate this model in other regions. Doctronic has confirmed it is in discussions with regulators and government bodies in other states to expand its AI prescription services. This strategic effort aims to scale its proven capabilities and set a new standard for AI's role in routine medical administration.
Navigating the National Regulatory Landscape
The company's state-level progress aligns with emerging discussions at the federal level regarding AI in medicine. Last year, proposed legislation was introduced in the U.S. House of Representatives to authorize AI and machine learning to prescribe FDA-approved drugs autonomously. The bill, titled the "Healthy Technology Act of 2025," was sponsored by Representative David Schweikert of Arizona.
If enacted, this legislation would formally recognize AI as a "practitioner licensed by law to administer such drugs," fundamentally altering the regulatory framework. The bill has since been referred to the Committee on Energy and Commerce for further consideration. This legislative movement reflects a broader, national conversation about integrating advanced technology into highly regulated fields like healthcare.
Doctronic's successful Series B funding round empowers it to accelerate its mission of transforming healthcare delivery through artificial intelligence. The company is uniquely positioned at the intersection of technological innovation, patient care, and complex regulatory navigation. As it expands its services and partnerships, Doctronic continues to shape the future of accessible and efficient medical services.